|drug1527||Hydroxychloroquine Sulfate Wiki||0.29|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
This is a three-arm randomized trial comparing the efficacy of single agent hydroxychloroquine to the combination of hydroxychloroquine and azithromycin, and to a delayed hydroxychloroquine regimen, which will serve as a contemporaneous Day 1-6 supportive care control, in eliminating detectable SARS-CoV-2 on day 6 following the initiation of treatment in order to determine which regimen is more effective.
Description: Will be assessed at day six compared to baseline between hydroxychloroquine sulfate alone and hydroxychloroquine sulfate plus azithromycin to treat COVID-19.Measure: Changes in patients viral load Time: Baseline, day 3 and day 6
Description: A second concurrent comparison will evaluate change in viral load at day 6 between hydroxychloroquine sulfate alone and supportive care.Measure: Second evaluation of changes in patients viral load Time: Day 6
Description: Time to resolution of symptomsMeasure: Symptom questionnaire Time: up to 6 months
Description: Change in the fever curve resulting in shorter time to afebrile for 48 hoursMeasure: Fever assessment Time: up to 10 days
Description: Body temperature will be measured in degrees Fahrenheit using an automated thermometer which will be provided to the patient 4 times per day.Measure: Vital Signs - Body Temperature Time: up to 10 days
Description: Time to discharge (If hospitalized)Measure: Discharge Time: up to 6 months
Description: Time to recovery (back to school, work, etc)Measure: Recovery Time: up to 6 months
Description: As measured by standard metricsMeasure: Assessment of agent toxicity Time: up to 10 days
Description: Collection of Oropharynx swabs for viral load and microbiome analysisMeasure: Oropharynx swab sample collections Time: up to 10 days
Description: Collection of blood for viral load and microbiome analysisMeasure: Blood Sample collections Time: up to 10 days
Description: Decrease in virus shedding in nasopharyngeal secretions such as Ferritin, D-dimer, CRP, Troponin and LDHMeasure: Viral shedding assessment - nasopharyngeal secretions Time: up to 10 days
Description: Decrease in virus shedding in serology such as Ferritin, D-dimer, CRP, Troponin and LDHMeasure: Viral shedding assessment - serology Time: up to 10 days
Description: Measurement of cytokines in bloodMeasure: Cytokines in blood Time: up to 10 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports